DOI: 10.1001/jamahealthforum.2023.2798 ISSN:
Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations
Kerstin N. Vokinger, Gellért Perényi, Olivier J. Wouters- Public Health, Environmental and Occupational Health
- Health Policy
This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower.